Citrate anticoagulation protocol to stabilize electrolytes during continuous renal replacement in ICU adults
Validation of a Regional Citrate Anticoagulation Protocol in Critically Ill Patients on Continuous Renal Replacement Therapy
This test tries to see if a modified CRRT method using citrate anticoagulation with post-filter replacement keeps electrolytes more stable and reduces the need for supplements in adult ICU patients with acute kidney injury.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 43 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Academic / other |
| Locations | 1 site (Barcelona, Barcelona) |
| Trial ID | NCT07514650 on ClinicalTrials.gov |
What this trial studies
Electrolyte disturbances are common during CRRT with regional citrate anticoagulation and can increase the need for electrolyte supplementation. This non-randomized, sequential interventional comparison tests CVVHDF with post-filter replacement against historical controls treated with standard CVVHD. Adult patients (≥18) admitted to the multidisciplinary ICU at Hospital de la Santa Creu i Sant Pau who require CRRT and can receive citrate anticoagulation are included. The primary outcome is reduction in electrolyte supplementation during the period of CRRT, with data collection ending when CRRT is discontinued.
Who should consider this trial
Good fit: Adults (≥18) in the Hospital de la Santa Creu i Sant Pau ICU with acute kidney injury requiring CRRT who can safely receive regional citrate anticoagulation are ideal candidates.
Not a fit: Patients with contraindications to citrate anticoagulation (for example severe liver failure), those who are pregnant or breastfeeding, or patients who do not require CRRT are unlikely to benefit.
Why it matters
Potential benefit: If successful, the protocol could reduce electrolyte losses and lower the need for intravenous electrolyte supplementation, potentially decreasing complications and nursing interventions.
How similar studies have performed: Regional citrate anticoagulation has been shown in prior studies to improve filter life and metabolic control during CRRT, but the specific CVVHDF post-filter replacement modification tested here has limited prior data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Age ≥18 years * Admission to the intensive care unit (ICU) * Diagnosis of acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) * Use of regional citrate anticoagulation during CRRT Exclusion Criteria * Known allergy or intolerance to citrate * Contraindications to citrate anticoagulation (e.g., severe liver failure or severe metabolic disorders affecting citrate metabolism) * Pregnancy or breastfeeding
Where this trial is running
Barcelona, Barcelona
- Hospital de la Santa Creu i Sant Pau — Barcelona, Barcelona, Spain (Recruiting)
Study contacts
- Study coordinator: Ana Jiménez Valenzuela, Nurse
- Email: ajimenezva@santpau.cat
- Phone: +34935537796
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.